Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice Daniel S. ZaharkoJoseph M. Covey Preclinical Studies Pages: 323 - 329
Comparison of the activity of Arabinosyl-5-azacytosine, Arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia John S. DriscollDavid G. JohnsJacqueline Plowman Preclinical Studies Pages: 331 - 334
Comparative cytotoxicity between cisplatin and second generation platinum analogs Benjamin DrewinkoLi-Ying YangJose M. Trujillo Preclinical Studies Pages: 335 - 340
Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay Fumihiko KanzawaYuka MatsushimaNaoto Miyazawa Preclinical Studies Pages: 341 - 347
Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion Gerald BatistRaymond W. Klecker Jr.Jerry M. Collins OriginalPaper Pages: 349 - 355
Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias Cristiana SessaLeander TschoppFranco Cavalli OriginalPaper Pages: 357 - 359
Human pharmacokinetics of esorubicin (4′ -deoxydoxorubicin) P. DodionT. A. DavisN. R. Bachur OriginalPaper Pages: 361 - 368
Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON) Aquilur RahmanFrederick P. SmithPaul V. Woolley OriginalPaper Pages: 369 - 374
Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyl) urea (CGP 15720A) L. PendyalaS. MadajewiczP. J. Creaven OriginalPaper Pages: 375 - 381
A phase I trial of ametantrone acetate (NSC-287513) Richard A. GamsFrederick OstroyAntonio J. Grillo-López OriginalPaper Pages: 383 - 388
A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck John L. EckenrodeRichard H. WheelerArlene A. Forastiere OriginalPaper Pages: 389 - 392
Phase II trial of bisantrene in non-small cell lung cancer Thomas P. MillerFrederick R. AhmannDavid S. Alberts OriginalPaper Pages: 393 - 395
Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma David A. AmatoErnest C. BordenHarvey J. Lerner OriginalPaper Pages: 397 - 401
Echinomycin: The first bifunctional intercalating agent in clinical trials Brenda J. FosterKathleen Clagett-CarrBrian Leyland-Jones OriginalPaper Pages: 403 - 410